Geographic Atrophy

The LMDD Eye Health Scorecard specifically evaluated insurance coverage for treatments addressing GA, neovascular AMD, and thyroid eye disease.

The results of an investigation into iRORA identified a wide spectrum of fundus autofluorescence patterns that corresponded with iRORA lesions and that those patterns were associated with conversion to cRORA over time.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

Topline results from the MAGNIFY phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

With the acquisition, Topcon Healthcare also assumes RetInSight’s AI algorithms that analyze retinal images to detect and monitor disease.

The first 6 patients in the study had an average improvement of 14.9 letters in early treatment diabetic retinopathy study (ETDRS) standard vision tests within 4 to 6 months post transplantation.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, presented available treatment options and what is coming down the pipeline for retinal conditions.

Results from a recent study led researchers to advise clinicians of the potential for dystrophies that mimic age-related macular degeneration and other atrophic macular pathologies to be incorrectly diagnosed, which can impact treatment.

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

The company also reported a positive outcome of an analysis of masked data from its ongoing MAGNIFY Phase 2 trial for zervimesine in adults with GA.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

The potential gene therapy candidate is being evaluated for geographic atrophy.

This year was brimming with advancements in eye care.

The global survey revealed similar challenges for individuals with unilateral and bilateral geographic atrophy.

Brush up your geographic atrophy knowledge with our 2024 content highlights.